The Comparison of Two Challenging Low Dose APIs in a Continuous Direct Compression Process

Area of Science:

• Pharmaceutical Technology
• Materials Science

Background:

• Segregation and achieving homogenous mixtures are significant challenges in batch-based direct compression (BDC), particularly for low-dose tablet manufacturing.
• The physical properties of active pharmaceutical ingredients (APIs) can influence powder mixture behavior and processing outcomes.

Purpose of the Study:

• To evaluate the efficacy of continuous direct compression (CDC) as a solution for segregation problems in low-dose tablet production.
• To demonstrate the feasibility of a universal platform formulation for manufacturing low-dose tablets via CDC.

Main Methods:

• Comparative analysis of batch-based direct compression (BDC) and continuous direct compression (CDC) processes.
• Powder analysis to characterize the physical properties of APIs and their mixtures.
• Manufacturing and quality assessment of low-dose tablets using different APIs and process parameters.

Main Results:

• Continuous direct compression (CDC) successfully produced tablets with desired quality parameters for both APIs studied, mitigating segregation issues.
• API physical properties influenced powder mixture characteristics and processing, but process parameters like mixer impeller speed did not significantly impact end-product quality.
• A universal platform formulation proved feasible for low-dose tablet production using CDC.

Conclusions:

• Continuous direct compression (CDC) presents a viable and effective strategy to overcome segregation challenges inherent in batch-based direct compression (BDC) for low-dose tablets.
• The development and application of a universal platform formulation are feasible for efficient low-dose tablet manufacturing through CDC.